Key result
Innovance and LumiraDx D-dimer assays safely excluded pulmonary embolism using age-adjusted cutoffs similarly to VIDAS, with failure rates <2% across all tests.
Why the study?
Following evidence from ADJUST-PE on age-adjusted D-dimer cutoffs to exclude pulmonary embolism using the VIDAS assay, the safety of other D-dimer assays using age-adjusted cutoffs needed evaluation.
Do different D-dimer assays using age-adjusted cutoffs safely exclude pulmonary embolism compared to the VIDAS assay in patients evaluated for PE?
Observational (n=597)
Yes
Do different D-dimer assays using age-adjusted cutoffs safely exclude pulmonary embolism compared to the VIDAS assay in patients evaluated for PE?
Innovance and LumiraDx D-dimer assays with age-adjusted cutoffs are as safe as the VIDAS assay for excluding pulmonary embolism, whereas STA Liatest and Tina-quant may have higher false-negative rates.
BACKGROUND: The multicenter prospective ADJUST-PE study proved the safety of an age-adjusted D-dimer (AADD) cutoff to exclude pulmonary embolism (PE). OBJECTIVES: Assess the safety of different D-dimer (DD) assays using AADD in patients included in ADJUST-PE in Geneva compared with the originally used VIDAS DD Exclusion test. METHODS: This was a preplanned secondary analysis. The VIDAS DD Exclusion test was repeated to ensure reproducible results in thawed samples. Other tests performed were Innovance DD test, STA Liatest, Tina-quant DD, and the point-of-care LumiraDx test. The main outcome was venous thromboembolic risk (VTE) at initial testing or within 3 months after PE exclusion by a negative DD test using AADD ("failure rate"). The secondary outcome measure was to compare each assay with VIDAS in the classification of patients as having a negative vs positive AADD result. RESULTS: A total of 602 patients were included and 597 were available for analysis. Fourteen percent had PE confirmed at baseline. Failure rates were <2% for all tests. The risk of a change in classification from positive original VIDAS AADD to negative AADD result was similar to the repeated VIDAS (comparator) for Innovance and LumiraDx and higher for STA Liatest and Tina-quant. For the latter 2 assays, 3 and 5 patients with negative AADD had PE, respectively. CONCLUSION: Innovance and LumiraDx assays had similar safety in excluding PE by AADD compared with VIDAS. STA Liatest and Tina-quant classified a higher proportion of patients with a negative AADD, among whom 3 and 5 had PE, respectively.
No takes yet. Share an insight, caveat, or question.
Robert‐Ebadi et al. (2025) conducted an observational in Pulmonary embolism (n=597). Different D-dimer assays (Innovance, STA Liatest, Tina-quant, LumiraDx) vs. VIDAS D-dimer Exclusion test was evaluated on Venous thromboembolic risk (VTE) at initial testing or within 3 months after PE exclusion by a negative D-dimer test using age-adjusted cutoffs. Innovance and LumiraDx D-dimer assays safely excluded pulmonary embolism using age-adjusted cutoffs similarly to VIDAS, with failure rates <2% across all tests.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: